Mary Eugenia Rinella

Professor, Medicine, Hepatology Division

Emailm-rinella@northwestern.edu

Source: Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Certifications and Licenses

	Transplant Hepatology
	Gastroenterology

Training Experience

1999	Residency, University of Chicago Hospitals
2002	Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

MD, University of Illinois at Chicago

… → 1996

Medicine, MD, University of Illinois at Chicago

… → 1996

Research interests

Colonoscopy
Esophagogastroduodenoscopy (EGD)
Hepatitis
Liver Biopsy
Liver/Hepatic Disease
Non-Alcoholic Fatty Liver Disease
Variceal Banding
Viral Hepatitis

Fingerprint

Dive into the research topics where Mary Eugenia Rinella is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

4 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

15 Active
28 Finished

Prot#EDP 305-102: A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects with Liver-Biopsy Proven Non-Alcoholic Steatohepatitis (NASH)”
Rinella, M. E.
ICON Clinical Research, LLC, Enanta Pharmaceuticals, Inc.
7/31/20 → 7/31/23
Project: Research project
Prot# MGL-3196-14: A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
Rinella, M. E.
Pharmaceutical Research Associates, Inc., Madrigal Pharmaceuticals, Inc.
7/28/20 → 7/28/23
Project: Research project
Prot#VK2809-202: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects with Biopsy Proven Non-Alcoh
Rinella, M. E.
Covance Inc., Viking Therapeutics, Inc.
3/4/20 → 3/4/23
Project: Research project
Prot# Aramchol-018: A Phase 3/4, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH)
Rinella, M. E.
Covance Inc., Galmed Research and Development Ltd.
12/23/19 → 12/23/23
Project: Research project
Prot# MGL-3196-11: A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic
Rinella, M. E.
Pharmaceutical Research Associates, Inc., Madrigal Pharmaceuticals, Inc.
12/20/19 → 12/20/22
Project: Research project

6568 Citations
52 Article
21 Review article
7 Editorial
2 Letter
More
- 1 Comment/debate

Thanks to CLD for Small Favors: Reduced CVD Risk in Patients Awaiting Liver Transplantation
Shroff, H. & Rinella, M. E., Jan 2021, In: Digestive diseases and sciences. 66, 1, p. 7-9 3 p.
Research output: Contribution to journal › Editorial › peer-review

Open Access
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Pedrosa, M., Seyedkazemi, S., Francque, S., Sanyal, A., Rinella, M., Charlton, M., Loomba, R., Ratziu, V., Kochuparampil, J., Fischer, L., Vaidyanathan, S. & Anstee, Q. M., Jan 2020, In: Contemporary Clinical Trials. 88, 105889.
Research output: Contribution to journal › Article › peer-review

Open Access
18 Scopus citations
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Patel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W. S., Greenbloom, S., Jayakumar, S., Shiffman, M. L., Freilich, B., Lawitz, E. J., Gane, E. J., Harting, E., Xu, J., Billin, A. N., Chung, C., Djedjos, C. S., Subramanian, G. M. & 4 others, Myers, R. P., Middleton, M. S., Rinella, M. & Noureddin, M., Jul 1 2020, In: Hepatology. 72, 1, p. 58-71 14 p.
Research output: Contribution to journal › Article › peer-review
25 Scopus citations
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices
Younossi, Z. M., Corey, K. E., Alkhouri, N., Noureddin, M., Jacobson, I., Lam, B., Clement, S., Basu, R., Gordon, S., Ravendhra, N., Puri, P., Rinella, M., Scudera, P., Singal, A. K. & Henry, L., Aug 1 2020, In: Alimentary Pharmacology and Therapeutics. 52, 3, p. 513-526 14 p.
Research output: Contribution to journal › Article › peer-review
4 Scopus citations
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension
The Belapectin (GR-MD-02) Study Investigators, Apr 2020, In: Gastroenterology. 158, 5, p. 1334-1345.e5
Research output: Contribution to journal › Article › peer-review

Open Access
30 Scopus citations